Q-omics provides the consensus-scored TTC25 profile across patient tissues and cancer cell-line models. TTC25 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TTC25 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TTC25 RNA expression shows 18,575 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where TTC25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC25 survival associations across molecular data types. TTC25 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC25 RNA expression–survival associations across cancer types. High TTC25 expression shows unfavorable associations in LGG and KICH, but favorable associations in BRCA, ACC, KIRC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for TTC25 RNA expression.
This table summarizes TTC25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC25 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in KIRC and KIRP. The KICH box plot shows higher TTC25 RNA expression in normal versus tumor tissue (log2 FC = −2.157, t-test p < 0.001).
This table shows molecular features associated with TTC25 in patient tissues and cancer cell lines. In patient samples, TTC25 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
